[2015-2019年中国河南省癌症患者5年相对生存率]。

Q Chen, M X Zhang, L W Guo, L Y Zheng, C Y Liu, Y X Wang, Y Liu, H Wang, H F Xu, R H Kang, X Y Wang, S Z Liu, S K Zhang
{"title":"[2015-2019年中国河南省癌症患者5年相对生存率]。","authors":"Q Chen, M X Zhang, L W Guo, L Y Zheng, C Y Liu, Y X Wang, Y Liu, H Wang, H F Xu, R H Kang, X Y Wang, S Z Liu, S K Zhang","doi":"10.3760/cma.j.cn112152-20231024-00237","DOIUrl":null,"url":null,"abstract":"<p><p><b>Objective:</b> To analyze the 5-year relative survival rate of cancer in Henan province based on cancer registration data. <b>Methods:</b> Cancer survival data were extracted from the cancer registration database of Henan province with the diagnosis date between January 1, 2010 and December 31, 2019 were included. The closing date of follow-up was set as December 31, 2019. The 5-year relative survival rate of cancer was calculated using the period survival analysis method and the Ederer II method in the R package \"periodR\", and the interest period was between 2015 and 2019. <b>Results:</b> During the period of 2015-2019, the overall 5-year relative survival rate of cancer patients in Henan province was 43.6%, and after age-standardization, it was 40.2%. The overall 5-year relative survival rate showed the characteristics of higher survival rate in females than males (45.9% vs 34.7%, <i>Z</i>=39.60, <i>P</i><0.001) and higher survival rate in urban areas than rural areas (44.9% vs 39.1%, <i>Z</i>=12.97, <i>P</i><0.001). The 5-year relative survival rate for cancer patients among children aged 0-14 was 60.2%, and for adults aged 15 and above, it was 43.5%, which was standardized to 40.2% after age adjustment. There are two types of cancers with a standardized 5-year relative survival rate exceeding 70% (thyroid cancer at 82.2% and breast cancer at 71.6%), and four cancers with a rate below 30% (pancreatic cancer at 18.2%, liver cancer at 19.6%, lung cancer at 24.0%, and gallbladder cancer at 26.6%). <b>Conclusion:</b> The cancer 5-year survival rate in Henan Province is lower than that of the national average, indicating the need for continued enhancement of cancer prevention and control measures.</p>","PeriodicalId":39868,"journal":{"name":"中华肿瘤杂志","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[The 5-year relative survival rate among cancer patients in Henan province of China, 2015-2019].\",\"authors\":\"Q Chen, M X Zhang, L W Guo, L Y Zheng, C Y Liu, Y X Wang, Y Liu, H Wang, H F Xu, R H Kang, X Y Wang, S Z Liu, S K Zhang\",\"doi\":\"10.3760/cma.j.cn112152-20231024-00237\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Objective:</b> To analyze the 5-year relative survival rate of cancer in Henan province based on cancer registration data. <b>Methods:</b> Cancer survival data were extracted from the cancer registration database of Henan province with the diagnosis date between January 1, 2010 and December 31, 2019 were included. The closing date of follow-up was set as December 31, 2019. The 5-year relative survival rate of cancer was calculated using the period survival analysis method and the Ederer II method in the R package \\\"periodR\\\", and the interest period was between 2015 and 2019. <b>Results:</b> During the period of 2015-2019, the overall 5-year relative survival rate of cancer patients in Henan province was 43.6%, and after age-standardization, it was 40.2%. The overall 5-year relative survival rate showed the characteristics of higher survival rate in females than males (45.9% vs 34.7%, <i>Z</i>=39.60, <i>P</i><0.001) and higher survival rate in urban areas than rural areas (44.9% vs 39.1%, <i>Z</i>=12.97, <i>P</i><0.001). The 5-year relative survival rate for cancer patients among children aged 0-14 was 60.2%, and for adults aged 15 and above, it was 43.5%, which was standardized to 40.2% after age adjustment. There are two types of cancers with a standardized 5-year relative survival rate exceeding 70% (thyroid cancer at 82.2% and breast cancer at 71.6%), and four cancers with a rate below 30% (pancreatic cancer at 18.2%, liver cancer at 19.6%, lung cancer at 24.0%, and gallbladder cancer at 26.6%). <b>Conclusion:</b> The cancer 5-year survival rate in Henan Province is lower than that of the national average, indicating the need for continued enhancement of cancer prevention and control measures.</p>\",\"PeriodicalId\":39868,\"journal\":{\"name\":\"中华肿瘤杂志\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-10-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中华肿瘤杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/cma.j.cn112152-20231024-00237\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华肿瘤杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/cma.j.cn112152-20231024-00237","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

目的根据癌症登记数据分析河南省癌症 5 年相对生存率。方法从河南省癌症登记数据库中提取确诊日期在 2010 年 1 月 1 日至 2019 年 12 月 31 日之间的癌症生存数据。随访结束日期定为 2019 年 12 月 31 日。采用R软件包 "periodR "中的周期生存分析方法和Ederer II方法计算癌症5年相对生存率,关注期为2015年至2019年。结果显示2015-2019年期间,河南省癌症患者总体5年相对生存率为43.6%,年龄标准化后为40.2%。总体5年相对生存率呈现女性高于男性(45.9% vs 34.7%,Z=39.60,P<0.001)、城市高于农村(44.9% vs 39.1%,Z=12.97,P<0.001)的特点。0-14岁儿童癌症患者的5年相对生存率为60.2%,15岁及以上成人癌症患者的5年相对生存率为43.5%,经年龄调整后标准化为40.2%。有两种癌症的标准化 5 年相对生存率超过 70%(甲状腺癌为 82.2%,乳腺癌为 71.6%),有四种癌症的标准化 5 年相对生存率低于 30%(胰腺癌为 18.2%,肝癌为 19.6%,肺癌为 24.0%,胆囊癌为 26.6%)。结论河南省的癌症 5 年生存率低于全国平均水平,表明需要继续加强癌症预防和控制措施。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[The 5-year relative survival rate among cancer patients in Henan province of China, 2015-2019].

Objective: To analyze the 5-year relative survival rate of cancer in Henan province based on cancer registration data. Methods: Cancer survival data were extracted from the cancer registration database of Henan province with the diagnosis date between January 1, 2010 and December 31, 2019 were included. The closing date of follow-up was set as December 31, 2019. The 5-year relative survival rate of cancer was calculated using the period survival analysis method and the Ederer II method in the R package "periodR", and the interest period was between 2015 and 2019. Results: During the period of 2015-2019, the overall 5-year relative survival rate of cancer patients in Henan province was 43.6%, and after age-standardization, it was 40.2%. The overall 5-year relative survival rate showed the characteristics of higher survival rate in females than males (45.9% vs 34.7%, Z=39.60, P<0.001) and higher survival rate in urban areas than rural areas (44.9% vs 39.1%, Z=12.97, P<0.001). The 5-year relative survival rate for cancer patients among children aged 0-14 was 60.2%, and for adults aged 15 and above, it was 43.5%, which was standardized to 40.2% after age adjustment. There are two types of cancers with a standardized 5-year relative survival rate exceeding 70% (thyroid cancer at 82.2% and breast cancer at 71.6%), and four cancers with a rate below 30% (pancreatic cancer at 18.2%, liver cancer at 19.6%, lung cancer at 24.0%, and gallbladder cancer at 26.6%). Conclusion: The cancer 5-year survival rate in Henan Province is lower than that of the national average, indicating the need for continued enhancement of cancer prevention and control measures.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
中华肿瘤杂志
中华肿瘤杂志 Medicine-Medicine (all)
CiteScore
1.40
自引率
0.00%
发文量
10433
期刊介绍:
期刊最新文献
[International comparison and assessment of the quality of drug clinical trial implementation in China based on scientific regulatory system]. [A case of primary giant gastrointestinal stromal tumor of the liver]. [Chinese multidisciplinary expert consensus on the rational use of surufatinib in clinical practice(2024 edition)]. [Clinical predictive value of PD-1/PD-L1-induced electrocardiogram changes for cardiotoxicity]. [CT measurement of blood perfusion in hepatocellular carcinoma: from basic principle, measurement methods to clinical application].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1